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RESEARCH
The influence of norepinephrine 
and phenylephrine on cerebral perfusion 
and oxygenation during propofol–remifentanil 
and propofol–remifentanil–dexmedetomidine 
anaesthesia in piglets
Mai Louise Grandsgaard Mikkelsen1*, Rikard Ambrus2, Rune Rasmussen3, James Edward Miles1, 
Helle Harding Poulsen1, Finn Borgbjerg Moltke4,5 and Thomas Eriksen1
Abstract 
Background: Vasopressors are frequently used to increase blood pressure in order to ensure sufficient cerebral 
perfusion and oxygenation (CPO) during hypotensive periods in anaesthetized patients. Efficacy depends both on 
the vasopressor and anaesthetic protocol used. Propofol–remifentanil total intravenous anaesthesia (TIVA) is com-
mon in human anaesthesia, and dexmedetomidine is increasingly used as adjuvant to facilitate better haemodynamic 
stability and analgesia. Little is known of its interaction with vasopressors and subsequent effects on CPO. This study 
investigates the CPO response to infusions of norepinephrine and phenylephrine in piglets during propofol–remifen-
tanil and propofol–remifentanil–dexmedetomidine anaesthesia. Sixteen healthy female piglets (25–34 kg) were 
randomly allocated into a two-arm parallel group design with either normal blood pressure (NBP) or induced low 
blood pressure (LBP). Anaesthesia was induced with propofol without premedication and maintained with propo-
fol–remifentanil TIVA, and finally supplemented with continuous infusion of dexmedetomidine. Norepinephrine and 
phenylephrine were infused in consecutive intervention periods before and after addition of dexmedetomidine. 
Cerebral perfusion measured by laser speckle contrast imaging was related to cerebral oxygenation as measured by 
an intracerebral Licox probe (partial pressure of oxygen) and transcranial near infrared spectroscopy technology (NIRS) 
(cerebral oxygen saturation).
Results: During propofol–remifentanil anaesthesia, increases in blood pressure by norepinephrine and phenyle-
phrine did not change cerebral perfusion significantly, but cerebral partial pressure of oxygen (Licox) increased 
following vasopressors in both groups and increases following norepinephrine were significant (NBP: P = 0.04, LBP: 
P = 0.02). In contrast, cerebral oxygen saturation (NIRS) fell significantly in NBP following phenylephrine (P = 0.003), 
and following both norepinephrine (P = 0.02) and phenylephrine (P = 0.002) in LBP. Blood pressure increase by both 
norepinephrine and phenylephrine during propofol–remifentanil–dexmedetomidine anaesthesia was not followed 
by significant changes in cerebral perfusion. Licox measures increased significantly following both vasopressors in 
both groups, whereas the decreases in NIRS measures were only significant in the NBP group.
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Main text
Background
Vasopressors are frequently used to increase blood pres-
sure in order to ensure sufficient cerebral perfusion and 
oxygenation (CPO) during hypotensive periods induced 
by e.g. anaesthesia or septic shock [1–4]. Two of the most 
commonly used vasopressors are norepinephrine and 
phenylephrine [5]. The quality of the response in cere-
bral blood flow (CBF) to vasopressor treatment has been 
shown to rely on the type of vasopressor used [3, 6, 7] 
and on the concurrent anaesthetic protocol [3].
Vasopressors have a well-documented systemic cardio-
vascular effect [8]. The primary benefit of vasopressors 
on CPO is believed to be due to the concomitant eleva-
tion of cerebral perfusion pressure following elevation 
of the systemic blood pressure [9]. However, if systemic 
pressure is kept within the limits of cerebral autoregula-
tion, vasopressor treatment should have little effect on 
cerebral perfusion, despite an increase in blood pres-
sure [9, 10]. Porcine cerebral arteries and veins have been 
reported to have dense sympathetic innervation and to 
be susceptible to vasopressor induced vasoconstriction 
in  vitro [11]. Vasopressor-induced vasoconstriction has 
also been reported in  vivo in healthy humans [12]. The 
sympathomimetic effect of norepinephrine is mediated 
by binding to both α-(α1) and β-(β1 and β2) adrenergic-
receptors, whereas phenylephrine is a highly selec-
tive α1-agonist. The cerebral veins are more sensitive to 
sympathetic activation than cerebral arteries, and vaso-
constriction are more specifically mediated by α2 rather 
than α1 adrenoceptors [11]. These differences may have 
contributed to the varying vasopressor effect on cerebral 
arteries versus veins observed in humans [12]. Despite 
the presence of α-adrenoceptors in the cerebral arteries, 
the vasoconstrictive effect of vasopressors on the cerebral 
arteries has been reported as clinically insignificant, since 
maximal stimulation has been shown to only reduce CBF 
by 5–10%, in healthy humans [10, 13].
General anaesthesia with propofol in combina-
tion with a potent opioid, such as remifentanil, has 
become increasingly popular [14] and the preferred 
total intravenous anaesthesia (TIVA) protocol in neu-
roanaesthesia and paediatric intensive care units [4, 
15]. Propofol alone or in combination with remifentanil 
has been shown to preserve cerebral autoregulation in 
anaesthetic doses in both human [16–18] and animal 
studies [19, 20], and may thus be favourable in experi-
mental studies requiring intact cerebral autoregulation. 
The α2-agonist, dexmedetomidine, has been receiving 
increasing attention as anaesthetic adjuvant in human 
anaesthesia and intensive care because of its abilities 
to preserve cerebral autoregulation and because of its 
near-ideal sedation. It has furthermore been recog-
nized for facilitating better haemodynamic stability, 
analgesia and neuroprotection [15, 21–24]. In veteri-
nary anaesthesia, α2-agonists have been widely used for 
many years as premedication, sedation and analgesia 
[25–27]. The hemodynamic effect of dexmedetomidine 
has shown to be both dose- and species dependent [28]. 
Dexmedetomidine has been shown to decrease sys-
temic blood pressure in both humans and animals and 
to cause a generalized decrease in CBF [29–34]. This 
has not consistently been associated with decreased 
cerebral metabolic rate of oxygen [30, 31] and concern 
has been raised that dexmedetomidine may have the 
potential to cause cerebral vasoconstriction [23, 35].
The potential interactive vasoconstrictive effect of 
vasopressors and anaesthetics on the cerebral vascu-
lature may be of concern in regard to CBF in hemo-
dynamically compromised or neurocritical patients 
[36, 37]. The effect of vasopressors on CBF may be 
influenced by anaesthesia if cerebral autoregulation is 
preserved (intravenous anaesthesia) or impaired (inha-
lation anaesthesia) [3, 16–18], the latter making CBF 
more blood pressure-dependent with high gas concen-
trations [38], or when used with anaesthetics that might 
precondition cerebral vasoconstriction (α2-agonists) 
[39]. The systemic adrenoceptor-mediated properties 
of norepinephrine and phenylephrine produce differ-
ent circulatory effects [40, 41]. Norepinephrine has 
been shown to improve myocardial function whereas 
phenylephrine decreases ventricular performance. In 
addition, norepinephrine appears to decrease microcir-
culatory blood flow to the abdominal organs, whereas 
phenylephrine does not [5]. Therefore, the choice of 
anaesthetic protocol in experimental animal studies 
should include consideration of such interactions to 
avoid adverse effects on CPO.
The objective of this study was to investigate the CPO 
response to vasopressor infusion with norepinephrine 
Conclusions: Cerebral partial pressure of oxygen measured by Licox increased significantly in concert with the 
vasopressor induced increases in blood pressure in healthy piglets with both normal and low blood pressure. Cerebral 
oxygenation assessed by intracerebral Licox and transcranial NIRS showed opposing results to vasopressor infusions.
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and phenylephrine during propofol–remifentanil 
and propofol–remifentanil–dexmedetomidine TIVA, 
in healthy piglets with normal and lowered blood 
pressure.
Methods
Study design and animals
Full study details and data regarding the entire study, and 
results regarding the effect of dexmedetomidine on CPO 
have been reported elsewhere [42] and are presented in 
Additional file  1. The same animals were used for the 
study of vasopressor effect on CPO in this study.
In summary: This study was designed as a non-blinded, 
randomized, two-arm parallel group, experimental ani-
mal trial (Fig.  1). Sixteen female slaughter piglets (Dan-
ish Landrace/Yorkshire/Duroc) with a body weight of 
25–34  kg were used. In one group, low blood pressure 
(LBP) was induced using caval block [43, 44], whereas in 
the other group normal blood pressure (NBP) was main-
tained. All animals were subjected to the same anaes-
thetic protocol and did not receive premedication prior 
to induction on the day of the experiment.
Anaesthesia
General anaesthesia was induced while the animals were 
still in their pen to minimise stress. A dosage of 4–8 mg/
kg propofol was given through a catheter placed in an 
auricular vein the day before the experiment. After 
endotracheal intubation, the animals were connected to a 
mechanical ventilator. End tidal  CO2  (EtCO2) was main-
tained between 35 and 50  mmHg. Fraction of inspired 
oxygen  (FiO2) was maintained around 0.8, and was cen-
trally supplied by an in-house generator.
General anaesthesia was maintained using a TIVA pro-
tocol with separate syringe pumps (Terumo, Terufusion 
Syringe Pump TE-331, Belgium) for propofol (12–20 mg/
kg/h) and remifentanil (20–45  µg/kg/h) TIVA. Doses 
were individually regulated to accomplish unresponsive-
ness to noxious stimuli (dewclaw pinching), with propo-
fol doses adjusted to control anaesthetic depth (assessed 
as lack of movement) and remifentanil doses adjusted 
to eliminate responses to noxious stimuli. Once ani-
mal preparation was completed, anaesthetic doses were 
kept unchanged. Dexmedetomidine was supplemented 
after the first half of the experiment (Fig. 1) with a bolus 
of 1 µg/kg given over 10 min followed by a fixed dose of 
0.7 µg/kg/h iv.
Surgical preparation and instrumentation
All invasive procedures were conducted after infiltra-
tion with a mixture of lidocaine and bupivacaine. After 
surgical cut down, the femoral artery was cannulated 
for invasive blood pressure monitoring and intermittent 
blood collection for blood gas analysis. An eight French 
Fig. 1 Experimental design. The experimental design and flow for the two groups (NBP normal blood pressure group, LBP low blood pressure 
group). Key time points are marked with arrows and vertical bars. Solid vertical bars show pre- or post-intervention baselines, where the red arrows 
indicate supplemental blood gas readings. Open vertical bars show vasopressor challenges. Yellow horizontal bar indicates period with propofol–
remifentanil TIVA, green horizontal bar indicates period with propofol–remifentanil–dexmedetomidine, and blue horizontal bar indicates period 
with induced hypotension. PCB pre-caval block, PR-1 baseline during propofol–remifentanil, NE-1 norepinephrine during propofol–remifentanil, 
PR-intvas after norepinephrine and wash-out period during propofol–remifentanil, PE-1 phenylephrine during propofol–remifentanil, PR-2 after 
phenylephrine wash-out period/pre-dexmedetomidine during propofol–remifentanil, PRD propofol–remifentanil–dexmedetomidine, NE-2 norepi-
nephrine during propofol–remifentanil, PRD-intvas after norepinephrine and wash-out period during propofol–remifentanil–dexmedetomidine, 
PE-2 phenylephrine during propofol–remifentanil–dexmedetomidine, PRD-end after phenylephrine and wash-out period during propofol–remifen-
tanil–dexmedetomidine (end of experiment)
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balloon-tipped catheter was placed in the femoral vein 
in all animals, with the balloon positioned in the caudal 
vena cava just below the heart. A urinary catheter with 
a closed collecting bag was placed to prevent bladder 
distension. Isotonic glucose solution was administered 
throughout the experiment at 2.5 mL/kg/h. A multipara-
metric bedside monitor recorded haemodynamic and 
respiratory variables every 30  s, and data were trans-
ferred to a personal computer using Datex-Ohmeda S/5™ 
Collect software (GE Healthcare, Helsinki, Finland). The 
collected variables were pulse rate, and mean arterial 
blood pressure (MAP), body temperature (oesophageal 
probe), fractionated inspired oxygen  (FiO2), and  EtCO2 
(Additional file  1). Electrocardiogram and peripheral 
oxygen saturation by pulse oximetry  (SpO2) measured on 
the tail or the lower lip were monitored for continuous 
assessment.
Cerebral perfusion and oxygenation (CPO) measures
A circular craniotomy (20–30 mm) was performed over 
the right parietal lobe with a 5 mm craniotome, and dura 
was removed. A laser speckle contrast imaging (LSCI) 
camera (MoorFLPI-2, Moor Instruments, Devon, UK) 
was used to measure cerebral perfusion semi quantita-
tively in laser speckle perfusion units (LSPU). The posi-
tion of the head of the animal remained unchanged 
throughout the experiment and the focus distance was 
25  cm. Cerebral partial pressure of oxygen  (PbrO2) was 
measured by an intracerebral Clark-type probe (Licox, 
Integra LifeSciences, New Jersey, USA) which was placed 
25  mm subdurally into the white matter and secured 
to the craniotomy edge with bone wax. Non-invasive 
measurement of cerebral oxygen saturation  (SbrO2) was 
obtained by near infrared spectroscopy (NIRS) (Invos 
5100, Covidien/Medtronic, Minneapolis, USA). A sensor 
was attached to the skin of the forehead on the left side 
of the animal, on the contralateral side to the Licox probe 
and the LSCI camera, and isolated from external light.
Experimental protocol
After instrumentation the Licox probe was equilibrated 
for a period of 2  h or until  PbrO2  >  25  mmHg, and fol-
lowed by baseline data collection (PR-1–NBP and PCB–
LBP) for all animals (Fig.  1). The blood pressure was 
lowered by caval block in the LBP group (by inflation of 
the balloon catheter in the vena cava) until a stable MAP 
of 50–60 mmHg was achieved, and an additional baseline 
was recorded in this group (PR-1–LBP). The caval block 
was maintained throughout the experiment for the LBP 
group, and was not subjected to further adjustments.
Vasopressor intervention followed the same 
sequence (norepinephrine followed by phenylephrine) 
in both groups and was repeated after initiation of 
dexmedetomidine infusion. Baseline recordings were 
obtained before and after each intervention or washout 
period (Fig.  1). The standard 30  min washout periods 
were conservatively chosen to allow the blood pres-
sure and the CPO measures to return to baseline values 
between vasopressor interventions, and were chosen 
based on the longest reported clinical effect time of 
15  min for phenylephrine [45]. Norepinephrine (1  mg/
mL Noradrenalin “SAD”, Amgros I/S, Copenhagen, 
Denmark) was administered by bolus (100  µg) and fol-
lowed by infusion of (0.6–2.0  µg/kg/min) to a target 
effect of either MAP 130–140 mmHg or 100% increase 
in MAP (primarily for the LBP group) from the base-
line. Similarly, phenylephrine (1  mg/mL Metaoxe-
drin “SAD”, Amgros I/S, Copenhagen, Denmark) was 
administered by bolus (200  µg) and followed by infu-
sion of 5.0–13.5  µg/kg/min to a target effect of either 
MAP  130–140  mmHg or 100% increase (primarily for 
the LBP group) in MAP from the baseline. During the 
experiment, arterial blood samples were collected at 
PCB, PR-1, PR-2, PRD and PRD-end for blood gas and 
acid–base evaluation (Fig.  1 and Additional file  1). All 
animals were euthanized with pentobarbital IV at the 
end of the experiment.
Statistics
Statistical analysis was performed using SPSS 24.0 soft-
ware  (IBM®  SPSS® Statistics for Mac, IBM Corp. ©, 
Armonk, NY, USA), and  Microsoft®  Excel® for Mac 
2011 version 14.3.9 (2010 Microsoft Corporation). Non-
parametric statistical tests were used, since normal dis-
tribution of data could not be assumed due to the small 
sample size. Data were reported as medians and range 
(min–max), and differences between groups were ana-
lysed by the independent-samples median test. Median 
changes for all outcome variables were reported with 95% 
confidence intervals (95% CI) using Hodges-Lehmann 
estimates where appropriate. Primary (Licox, NIRS and 
LSCI) and secondary (MAP, pulse rate and  EtCO2) out-
come variables at time points PR-1, NE-1, PR-intvas, 
PE-1, PRD, NE-2, PRD-intvas and PE-2 were compared 
using Friedman’s ANOVA with post hoc pairwise com-
parisons. Significance levels for the four comparisons 
of interest (before vasopressor and during vasopressor 
administration) were controlled using Holm–Bonfer-
roni’s correction before reporting. Significance was set at 
the 5% level.
A sample size of 16 animals, divided into two groups 
of 8, was calculated using conservative estimates based 
on earlier studies [46] with expected power of 80% in 
detecting a minimum of 30% difference in MAP with a 
two-tailed significance level of 5% after supplementation 
of dexmedetomidine.
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Results
All 16 animals completed the experimental protocol. 
Data from three (NBP group n = 2, LBP group n = 1) pig-
lets were excluded from analysis. One piglet developed 
signs of brain oedema with a severe reduction in CPO 
following craniotomy (LBP group). In the NBP group, 
one piglet had persistently and unexplainably high pulse 
rate,  EtCO2,  PaCO2 and a low pH, which were expected 
to produce an atypical CPO response. The other piglet 
was excluded due to technical difficulties.
The remaining 13 piglets reached the target MAP with 
vasopressor administration of  >  130  mmHg or a 100% 
increase over pre-treatment MAP. The animals of the 
two groups revealed no significant demographic differ-
ences, nor were any significant differences revealed in 
anaesthesia time, preparation time, anaesthetic doses, 
baseline  PbrO2 or LSPU measurements after equilibration 
[42]. Additionally, there was found no significant differ-
ence between the two groups in  SbrO2 measured by NIRS 
(P  =  0.59), which were 65% (range 59–72) in the LBP 
group and 62% (range 51–70) in the NBP group at PCB 
and PR-1 respectively. Both groups reached normal  PbrO2 
and  SbrO2 levels [47, 48] after equilibration.
Vasopressor effects under propofol–remifentanil anaesthesia
Norepinephrine administration significantly increased 
MAP in both groups [LBP: P =  0.002, median increase 
61  mmHg (95% CI 47; 71), NBP: P  =  0.009, median 
increase 51 mmHg (95% CI 39; 66)]. Following washout 
MAP was not significantly different to pre-treatment 
levels in either group (P = 1) with median differences of 
1 mmHg (95% CI − 8; 11) for LBP and 7 mmHg (95% CI 
− 6; 17) for NBP.
Phenylephrine administration significantly (P  =  0.03) 
increased MAP in the LBP group [median increase 
47  mmHg (95% CI 32; 66)] but not in the NBP group 
[P =  0.13, median increase 33  mmHg (95% CI 14; 55)] 
(Fig. 2a).
Pulse rate decreased significantly in both groups fol-
lowing phenylephrine (LBP: P  =  0.02, NBP: P  =  0.04) 
but not norepinephrine (LBP: P  =  0.4, NBP: P  =  0.6) 
(Fig. 2b).
Cerebral partial pressure of oxygen  (PbrO2) increased 
significantly following norepinephrine (P  =  0.02) but 
not phenylephrine (P = 0.06) in the LBP group (median 
increases 14 mmHg (95% CI 6; 26) and 11 mmHg (95% 
CI 2; 23), respectively). A similar response was observed 
in the NBP group with a significant increase following 
norepinephrine [P  =  0.04, median increase 17  mmHg 
(95% CI 5; 33)] but not phenylephrine [P = 0.2, median 
increase 8 mmHg (95% CI 2; 26)] (Fig. 3a).
In contrast, cerebral oxygen saturation  (SbrO2) fell sig-
nificantly in the LBP group following both norepineph-
rine and phenylephrine [P  =  0.02, median decrease 
−  11% (95% CI −  20; −  3) and P  =  0.002, median 
decrease − 15% (95% CI − 23; − 7), respectively] and in 
a b c
Fig. 2 Boxplots of haemodynamic data at baselines and vasopressor interventions. Absolute data presented as boxplots with median and inter-
quartile range. Open circles indicate outliers. All comparisons with significant changes between interventions and the immediate pre-intervention 
baselines are marked with horizontal solid lines and exact P values are noted. a mean arterial pressure (MAP), b pulse rate, c end-tidal carbon 
dioxide  (EtCO2). For all variables, the results of the normal blood pressure (NBP) are presented on the top chart and results from low blood pressure 
(LBP) group are presented at the bottom chart. The x-axis represents the experimental time-points, and the y-axis shows the names and units of the 
individual variables. NE-1/PE-1 norepinephrine/phenylephrine infusion during propofol–remifentanil, NE-2/PE-2 norepinephrine/phenylephrine infu-
sion during propofol–remifentanil–dexmedetomidine, PCB pre-caval block (only LBP), PR-1 baseline before interventions (after caval block in LBP), 
PR-intvas after NE-1 and 30-min washout, PR-2 after PE-1 and 30-min washout, PRD baseline after infusion start of dexmedetomidine, PRD-intvas 
after NE-2 and 30-min washout, PRD-end after PE-2 and 30-min washout
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the NBP group  SbrO2 fell significantly following phenyle-
phrine [P = 0.003, median decrease − 24% (95% CI − 31; 
− 22)] but not norepinephrine [P = 0.2, median decrease 
−  10% (95% CI −  16; −  6)] (Fig.  3b). LSCI measure-
ments (LSPU) did not exhibit a clear trend to increase or 
decrease, and no significant changes were observed fol-
lowing vasopressor administration (Fig. 3c).
While  EtCO2 readings showed increased variability 
in the LBP group compared to the NBP group, neither 
group’s  EtCO2 readings responded significantly to vaso-
pressor treatment (Fig. 2c).
Vasopressor effects under propofol–remifentanil–
dexmedetomidine anaesthesia
Norepinephrine administration significantly increased 
MAP in both groups [LBP: P  =  0.02, median increase 
46  mmHg (95% CI 17; 81), NBP: P  =  0.01, median 
increase 48 mmHg (95% CI 33; 57)]. Following washout 
MAP was not significantly different to pre-treatment 
levels in either group (P = 1.0) with median differences 
of − 6 mmHg (95% CI − 12; 3) for LBP and − 1 mmHg 
(95% CI − 5; 4) for NBP.
Phenylephrine administration significantly increased 
MAP in both groups [LBP: P  =  0.03, median increase 
44  mmHg (95% CI 20; 66), NBP: P  =  0.01, median 
increase 48 mmHg (95% CI 34; 62)] (Fig. 2a).
Pulse rate did not alter significantly in either group 
with either vasopressor in the NBP group, but fell 
significantly following phenylephrine in the LBP group 
[P  =  0.05, median decrease −  25 (95% CI −  66; 34)] 
(Fig. 2b).
Cerebral partial pressure of oxygen  (PbrO2) increased 
significantly in the LBP group following both norepi-
nephrine and phenylephrine [P = 0.001, median increase 
18 mmHg (95% CI 11; 28) and P = 0.003, median increase 
16  mmHg (95% CI 7; 42)]. In the NBP group, a similar 
response was seen with significant increases seen follow-
ing norepinephrine [P = 0.02, median increase 13 mmHg 
(95% CI 6; 23)] and phenylephrine [P  =  0.03, median 
increase 10 mmHg (95% CI − 2; 16)] (Fig. 3a).
Cerebral oxygen saturation  (SbrO2) did not fall signifi-
cantly in the LBP group following either norepinephrine 
[P =  0.08, median decrease −  7% (95% CI −  20; 1)] or 
phenylephrine [P  =  0.14, median decrease −  7% (95% 
CI − 17; − 1)]. In contrast, the NBP group experienced 
significant decreases following both norepinephrine 
[P = 0.01, median decrease − 21% (95% CI − 26; − 18)] 
and phenylephrine [P  <  0.001, median decrease −  33% 
(95% CI −  37; −  30)] (Fig.  3b). As for the NBP group, 
LSCI did not measure any significant changes in cerebral 
perfusion (LSPU) following vasopressor administration 
(Fig. 3c).
The LBP group continued to exhibit increased variabil-
ity in  EtCO2 readings compared to the NBP group, but 
no significant changes were observed due to vasopressor 
administration (Fig. 2c).
a b c
Fig. 3 Boxplots of CPO data at baselines and vasopressor interventions. Absolute data presented as boxplots with median and interquartile range. 
Open circles indicate outliers. All comparisons with significant changes between interventions and the immediate pre-intervention baselines are 
marked with horizontal solid lines and exact p-values are noted. a Licox, b near infrared spectroscopy (NIRS), c laser speckle contrast imaging (LSCI). 
For all variables, the results of the normal blood pressure (NBP) are presented on the top chart and results from low blood pressure (LBP) group are 
presented at the bottom chart. The x-axis represents the experimental time-points, and the y-axis shows the names and units of the individual vari-
ables. NE-1/PE-1 Norepinephrine/phenylephrine infusion during propofol–remifentanil, NE-2/PE-2 Norepinephrine/phenylephrine infusion during 
propofol–remifentanil–dexmedetomidine, PCB pre-caval block (only LBP), PR-1 baseline before interventions (after caval block in LBP), PR-intvas after 
NE-1 and 30-min washout, PR-2 after PE-1 and 30-min washout, PRD baseline after infusion start of dexmedetomidine, PRD-intvas after NE-2 and 
30-min washout, PRD-end after PE-2 and 30-min washout
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Discussion
Cerebral partial pressure of oxygen  (PbrO2) was found to 
increase during vasopressor challenges when assessed by 
Licox, while cerebral oxygen saturation  (SbrO2) decreased 
when assessed by NIRS. Cerebral perfusion (LSPU) was 
not found to change significantly in concert with the 
vasopressor induced increases in MAP. This pattern 
of findings was similar in both groups and during both 
TIVA protocols (Fig.  3c), suggesting that the cerebral 
autoregulation did remain intact throughout the experi-
ment. This is consistent with the findings of Bruins et al. 
[3] indicating preserved cerebral autoregulation during 
TIVA (midazolam and fentanyl), in contrast to inhalation 
anaesthesia (isoflurane-based) where autoregulation was 
impaired.
The increase in  PbrO2 during norepinephrine or phe-
nylephrine has been previously reported in pigs with 
both uninjured brains [49] and traumatic brain injury [7]. 
In the present study, the significant increase in  PbrO2 dur-
ing vasopressor infusion was not accompanied by a con-
current increase in perfusion, suggesting that changes in 
 PbrO2 do not simply reflect changes in CBF [50]. Decreas-
ing  SbrO2 with increasing  PbrO2 was observed during 
vasopressor infusions, in both the propofol–remifenta-
nil and propofol–remifentanil–dexmedetomidine TIVA 
groups (Fig. 3a, b). These results are consistent with find-
ings in human NIRS studies, where a decrease in  SbrO2 in 
response to blood pressure elevation by norepinephrine 
[51] or phenylephrine [6, 12, 52, 53] has been reported. 
Human studies of NIRS have also reported increase 
in  SbrO2 after nitroprusside induced blood pressure 
decrease and decrease in  SbrO2 in response to vasopres-
sor induced increase in blood pressure [54, 55]. Some 
authors speculated that this response in cerebral oxygen 
saturation was part of a normal cerebral autoregulatory 
response [54], while others have questioned the valid-
ity of NIRS technology and suggested that it primarily 
reflects skin perfusion rather than cerebral oxygenation 
[12, 37, 56–59]. Cerebral oxygen saturation values  (SbrO2) 
and cerebral partial pressure of oxygen values  (PbrO2) are 
not directly comparable in absolute values, since NIRS 
reflects levels of oxygen-saturated haemoglobin in the 
venous, capillary and arterial blood [60] and Licox has 
been described as a measure of “the pool of oxygen” that 
accumulates in the brain tissue and thus reflects the bal-
ance between oxygen delivery, diffusion and consumption 
[50, 61, 62]. The distribution ratio of arteries versus veins 
in the cerebral cortex is approximately 30:70, and NIRS 
therefore predominantly reflects the cerebral venous oxy-
gen reserve [60, 63]. Transcranial assessment of the cere-
bral oxygen saturation in piglets will furthermore depend 
on factors like skull thickness and pneumatisation of the 
frontal sinus, since NIRS has limited penetration. Due 
to the size and age of the animals used in this study, the 
pneumatisation of the large frontal sinus, which starts at 
approximately 3–4 months of age in domestic swine [64], 
was not expected to affect the results. NIRS purportedly 
reflects  SbrO2 in the grey matter of the cerebral cortex, 
whereas Licox measures  PbrO2 in the less metabolically 
active white matter of the CNS, areas with different met-
abolic activity and blood flow [9, 65, 66].
The differences in cerebral oxygenation assessment by 
Licox and NIRS could indicate that vasopressor treat-
ment affects the cortex and the white matter differently. 
Whether this is a normal response attributable to a pre-
served cerebral autoregulation [54] or related to limita-
tions of the methods used remains unanswered. Since 
cutaneous vessels predominantly have α-adrenergic 
innervation, treatment with vasopressors having high 
affinity for α-adrenergic receptors (such as norepineph-
rine and phenylephrine), results in vasoconstriction [67] 
and decreases in skin blood flow. Thus, decreases in cer-
ebral oxygen saturation values during vasopressor infu-
sion could therefore be a reflection of extra-cranial rather 
than cerebral oxygen saturation.
In summary, the CPO response to vasopressor chal-
lenge in piglets was found to be qualitatively similar for 
the two TIVA protocols used, and the concern regarding 
the potential additive vasoconstrictive effect of dexme-
detomidine during vasopressor infusions could not be 
confirmed in this study.
Strengths and limitations
The current study was strengthened by omission of pre-
medication on the day of experiment, by avoiding a pos-
sible vasoactive effect of premedication on CPO, and by 
using animals of the same sex and with a narrow age span 
since both age and gender may influences CBF in porcine 
models [68–70]. The results from this animal study best 
translates into children with neurodevelopmental matu-
rity of approximately 10 months of age [71, 72] and trans-
lation to other age groups should be made with caution 
[69, 73].
We compared regional with focal CPO measures 
and at contralateral brain sites in animals undergoing 
craniotomy, which limits derived conclusions regard-
ing global CPO status and regarding CPO in animals 
not undergoing craniotomy. Another potential limita-
tion was the possibility that the initial norepinephrine 
infusion could have affected the physiological and cer-
ebral response to the subsequent phenylephrine infu-
sions. However, the vasopressors were given in the 
same sequence in all the animals, and any potential 
preconditioning was therefore expected to be similar 
in the entire group of animals. The supra clinical tar-
get increases in blood pressure and infusion doses 
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of norepinephrine and phenylephrine in this study, 
were set to ensure an effect on CPO, if present, while 
retaining the animals within the expected blood pres-
sure range for intact cerebral autoregulation. The doses 
though, were comparable to doses used in other ani-
mal studies [7, 74]. This intensive approach to elevate 
blood pressure and subsequently CPO, when compared 
to having used more moderate targets and vasopres-
sor doses, may have increased the risk for type I errors. 
Furthermore, the design of the study was set up to illus-
trate haemodynamic influences in the normal as well 
as in hemodynamically compromised patients without 
initial brain pathologies. Extrapolation to situations 
with concurrent brain pathology should be made with 
caution since neurophysiology and cerebral autoregu-
lation may be different. The animals were subjected to 
prolonged anaesthesia, which for some animals lasted 
up to 10–11  h, and a mild to moderate hypercapnia 
was observed in all animals throughout the experi-
ment [42] (Additional file  1). The resulting respiratory 
acidosis would make the autoregulatory plateau nar-
rower, and thereby the cerebral perfusion more sensi-
tive to changes in blood pressure. This was however 
not evident from the results of the current study, since 
no significant variations in cerebral perfusion could be 
detected. The increased levels of  PaCO2 (represented 
by  EtCO2 in this study) might however have increased 
the variability of the perfusion data, which would make 
the non-significant findings expected. In general,  PbrO2 
showed greater variability and a tendency to increase 
in the NBP group than in the LBP group, especially 
after addition of dexmedetomidine. Finally, the sup-
plemented inspiratory oxygen levels were also relatively 
high in this study, with a  FiO2 of 0.8 for all animals 
(Additional file  1). The  FiO2 did not differ throughout 
the experiment, and is therefore not expected to influ-
ence the relative changes in  PbrO2 of this study. It can-
not be excluded that the CPO response to changes in 
MAP observed in this study could be different at lower 
 FiO2.
Non-significant P values following Holm-Bonferroni 
correction were noted for several parameters despite 
their confidence intervals for the change in medians 
not including zero. The small sample size and large var-
iability for some parameters  (PbrO2, LSPU, pulse rate) 
increased the risk of type II error. Confidence inter-
vals were therefore reported for both significant and 
non-significant changes, permitting a more nuanced 
interpretation.
Conclusions
Cerebral partial pressure of oxygen measured by Licox 
increased significantly in concert with the vasopressor 
induced increases in blood pressure in healthy piglets 
with both normal and low blood pressure. Cerebral oxy-
genation assessed by intracerebral Licox and transcranial 
NIRS showed opposing results to vasopressor infusions. 
The CPO responses, induced by norepinephrine and phe-
nylephrine, were shown to be qualitatively similar during 
both propofol–remifentanil and propofol–remifentanil–
dexmedetomidine TIVA.
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